Delving into the Latest Updates on KUR-111 with Synapse

Overview

Basic Info

Drug Type

Fusion protein

Synonyms

I-0401, KUR 111

Target

PTH1R

Action

agonists, stimulants

Mechanism

PTH1R agonists(Parathyroid hormone receptor agonists), Osteogenesis stimulants

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Fractures, Bone

Originator Organization

Kuros Biosciences Ltd.

Active Organization-

Inactive Organization

Kuros Biosurgery AG

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

For certain tibial plateau fractures the bone is compressed due to the force acting on the tibia during the accident. The void provoked by the compression of the bone is filled with an appropriate filling material and the fracture is fixated. I 0401 is a new bone graft substitute that has shown capacities to promote bone-healing. This study will test the safety and efficacy of I 0401 in the treatment of patients with tibial plateau fractures requiring grafting.

Start Date01 Nov 2006

Sponsor / Collaborator

Kuros Biosurgery AG

100 Clinical Results associated with KUR-111

Login to view more data

100 Translational Medicine associated with KUR-111

Login to view more data

100 Patents (Medical) associated with KUR-111

Login to view more data

100 Deals associated with KUR-111

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fractures, Bone	Phase 2	Australia	Kuros Biosurgery AG	01 Nov 2006
Fractures, Bone	Phase 2	France	Kuros Biosurgery AG	01 Nov 2006
Fractures, Bone	Phase 2	Germany	Kuros Biosurgery AG	01 Nov 2006
Fractures, Bone	Phase 2	Hungary	Kuros Biosurgery AG	01 Nov 2006
Fractures, Bone	Phase 2	Italy	Kuros Biosurgery AG	01 Nov 2006
Fractures, Bone	Phase 2	Poland	Kuros Biosurgery AG	01 Nov 2006
Fractures, Bone	Phase 2	Spain	Kuros Biosurgery AG	01 Nov 2006
Fractures, Bone	Phase 2	Switzerland	Kuros Biosurgery AG	01 Nov 2006
Fractures, Bone	Phase 2	United Kingdom	Kuros Biosurgery AG	01 Nov 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data